MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
IMMP

IMMP

Immutep Limited

$0.37
0
 (0%)
Exchange:  NASDAQ
Market Cap:  54.366M
Shares Outstanding:  40.729M
Delayed data
Calculate IMMP Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Marc Voigt
Full Time Employees:  41
Address: 
Australia Square
Sydney
NSW
2000
AU
Website:  https://www.immutep.com
Immutep Limited is a biotechnology enterprise focused on the exploration and advancement of medicinal candidates. The company specializes in creating immunotherapeutic solutions for treating both cancerous conditions and autoimmune disorders. Its primary investigational drug is eftilagimod alpha (referred to as efti or IMP321), a recombinant protein currently in a Phase IIb clinical trial, being assessed as a chemoimmunotherapy combination for metastatic breast cancer. Furthermore, Immutep is progressing several other programs: TACTI-002, which is undergoing Phase II clinical evaluation for head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003, in a Phase IIb clinical study for HNSCC; INSIGHT-004 and INSIGHT-003, both in Phase I clinical trials for solid tumors; and INSIGHT-005, a Phase I/IIa clinical trial for solid tumors. In addition to its oncology pipeline, the company’s portfolio includes IMP761, an agonist targeting lymphocyte activation gene 3 for autoimmune diseases; IMP701, an antagonist antibody designed to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody aimed at eliminating T cells implicated in autoimmunity. Immutep Limited has established collaborative ventures with prominent organizations such as GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., the Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. Incorporated in 1987 and headquartered in Sydney, Australia, the company was formerly known as Prima BioMed Ltd, adopting the name Immutep Limited in November 2017.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue3,505.7223,841.8775,043.774
Gross Profit1,443.904-37,704.847-56,366.759
EBITDA-39,572.091-44,544.368-62,876.848
Operating Income-77,688.492-88,104.186-126,421.795
Net Income-39,896.348-42,716.625-61,434.165

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets147,448.990201,579.281156,983.434
Total Liabilities10,979.60112,057.53913,348.071
Total Stockholders Equity136,469.389189,521.742143,635.363
Total Debt1,228.2681,593.7911,625.182
Cash and Cash Equivalents123,417.716161,790.14767,408.215

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-35,883-34,821.229-62,049.706
Capital Expenditure-47-932.369-45.769
Free Cash Flow-35,930-35,753.598-62,095.475
Net Income-39,896.348-42,716.625-61,434.165
Net Change in Cash43,42338,372.431-94,381.932

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)987,333.957Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)987,333.957Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)987,333.957Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-987,333.957Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-987,333.957Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-987,333.957Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)-57,937.206Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)-57,937.206Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)-57,937.206Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)10,264,695.594Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)10,264,695.594Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)10,264,695.594Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)-0.400Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)-0.400Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)-0.400Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)2Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
0  ?P/S
 (TTM)
: 
11.84
?Net Income
 (TTM)
: 
-27991687.58  ?P/E
 (TTM)
: 
-0.84
?Enterprise Value
 (TTM)
: 
149973  ?EV/FCF
 (TTM)
: 
0
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.69  ?ROIC
 (TTM)
: 
-1.22
?Net Debt
 (TTM)
: 
-120401777.2  ?Debt/Equity
 (TTM)
: 
0.02
?P/B
 (TTM)
: 
0.71  ?Current Ratio
 (TTM)
: 
2.97

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about IMMP valuation

Is Immutep Limited (IMMP) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Immutep Limited (IMMP) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is IMMP a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether IMMP trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is IMMP’s P/E ratio?

You can see IMMP’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for IMMP?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is IMMP a good long-term investment?

Whether IMMP fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

IMMP

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0
MARKETSnap

Trading Metrics:

Open: 0.36   Previous Close: 0.37
Day Low: 0.35   Day High: 0.37
Year Low: 0.29   Year High: 3.53
Price Avg 50: 0.45   Price Avg 200: 1.72
Volume: 502716   Average Volume: 14.319M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

IMMP Investor Alert - Immutep Limited Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit
09-06-2026 21:06
IMMP Investor Alert - Immutep Limited Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP
12-05-2026 16:55
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
07-05-2026 17:28
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP
03-06-2026 04:00
Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP
Robbins LLP Reminds IMMP Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Immutep Limited
05-06-2026 13:57
Robbins LLP Reminds IMMP Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Immutep Limited
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP
04-06-2026 23:18
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read